

Comparison of a Laboratory Developed Test with a CE Marked Commercial Kit for the Analysis of Complement Function and Inhibition

Ashley Frazer-Abel, Cynthia Marschner, Thomas Galway, Thuy Ton

Exsera BioLabs, Aurora Colorado




Purpose:

With the advent of complement targeting therapeutics, it has become increasingly important that robust complement function assays be available. Therefore we conducted a comparison of the two lead methods for measuring complement function: the historic hemolytic assays and the newer ELISA style deposition assays.



Background:

Complement is part of the innate immune system responsible for 1) killing some invading microbes; 2) directing the larger immune system to the site of infection; 3) tagging debris for clearance; 4) directing removal of host cellular debris and excess immune complexes. Because of these strong pro-inflammatory properties of complement, it is important that it is properly controlled.

Complement Pathway:




Principle of the Hemolytic Function Assay





This assay is a laboratory developed test

Principle of the ELISA Style Function Assay




This assay is CE marked but RUO marked in the USA

Relative Sensitivity: Classical Pathway Test





Classical Pathway: Repeat Measurements




Only 4% discordance on diagnostic category

80 Normals (40 males & 40 Females) were measured by both methods

Relative Sensitivity: Alternative Pathway Test



Alternative Pathway: Repeat Measurements



Only 6% discordance on diagnostic category

80 Normals (40 males & 40 Females) were measured by both methods

Intra-Assay & Inter-Assay Precision

Assay Precision, %CV			
Pathway	Level	Intra-Assay	Inter-Assay
CH50 Hemolytic	High	7.8%	NT
	Med	1.6%	6.0%
	Low	8.1%	NT
CP ELISA	High	6.2%	10.1%
	Med	2.6%	15.1%
	Low	2.2%	15.6%

Assay Precision, %CV			
Pathway	Level	Intra-Assay	Inter-Assay
AH50 Hemolytic	High	4.6%	NT
	Med	3.7%	6.0%
	Low	5.9%	NT
AP ELISA	High	6.0%	11.4%
	Med	1.8%	6.2%
	Low	1.7%	8.3%

A minimum of 15 repeat measurements were made by a minimum of two technologists. For inter-assay, measurements were made over at least 2 months.

Conclusions:

These two methods for measuring complement function performed comparably for assay precision. The hemolytic versions did demonstrate lower limits of quantitation. There was a disturbing lack of correlation between the two methods at the raw data level. However, this resulted in only a 4% and 6% discordance in the diagnostic category.

References:

- Kabat, E.A. and M.M. Mayer. 1961. Experimental Immunochemistry. Charles. C. Thomas, Springfield, IL, pp133-239.
- Rapp, H.J. and T. Borsos. 1970. Molecular Basis of Complement Action. Appleton-Century-Crofts, N.Y., N.Y. pp9-21, 111-134.
- Giclas, P.C. Manual of Clinical Laboratory Immunology 5th edition. Rose, NR, EC de Macario, JD Folds, HC Lane and RM Nakamura, Chapter 19, page 163, 1997.
- Harbeck, RJ and PC Giclas. 1991. Diagnostic Immunology Laboratory Manual. Raven press.
- Current Protocols in Immunology. Editors Coligan, JE, Kruisbeek, AM, Margulier, DH, Shevach, EM and Strober, W. Unit 13.1 Classical Pathway Evaluation.
- Mollnes TE et al. Complement analysis in the 21st century. Mol Immunol 2007; 44:3838-49.
- Nilsson B, Nilsson Ekdahl K. Complement Diagnostics: Concepts, Indications, and Practical Guidelines. Clin Develop Immunol; 2012, Art ID 962702.
- Seelen MA et al. Functional analysis of the classical, alternative and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005; 296:187-98.
- Salvador-Morales C, Sim RB. Handbook of Immunological Properties of Engineered Nanomaterials. 2013, 161 Ed, World Scientific Publishing [ISBN: 978-4390-25-5].

Contact Info: Ashley Frazer-Abel, PhD, D(ABMLI)
Ashley.Frazer-Abel@UCDenver.edu Phone: 303-724-7592